EPS-3903 / Enanta Pharma - LARVOL DELTA

Enanta nominated EPS-3903, a novel, potent and selective oral STAT6 inhibitor, as its lead development candidate for the treatment of atopic dermatitis and other diseases… (Businesswire) - "Preclinical data show EPS-3903 exhibited potent nanomolar activity in binding and cellular assays and was highly selective for STAT6. Importantly, EPS-3903 showed rapid, continuous and complete (>90%) inhibition of phosphorylated STAT6 (pSTAT6) after oral dosing in mice....Specifically, in a house dust mite asthma model, EPS-3903 resulted in complete (>90%) inhibition of lung pSTAT6 and decreased inflammation comparable to dupilumab....The Company is currently performing scale-up and IND enabling activities and targeting an IND filing in the second half of 2026."

IND • Pipeline update • Preclinical • Asthma • Atopic Dermatitis

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 (Businesswire) - "KIT inhibitors: (i) Enanta’s lead development candidate, EPS-1421:...The Company is currently conducting scale-up activities and IND enabling studies; (ii) STAT6 Inhibitors:...The Company plans to select a STAT6 development candidate in the second half of 2025; (iii) Enanta plans to expand its immunology pipeline with the introduction of a third program in 2025."

Pipeline update • Preclinical • Immunology

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 (Businesswire) - "EPS-1421, Enanta’s lead candidate, is a novel, potent and selective oral inhibitor of KIT, designed to treat chronic spontaneous urticaria and other indications...Enanta is conducting scale-up activities and IND enabling studies in 2025...The company will initially focus on atopic dermatitis and expand into other indications that block the IL-4/IL-13 signaling pathway, thereby addressing a primary driver of these diseases...The company is conducting lead optimization activities and plans to select a STAT6 lead candidate in the second half of 2025....Enanta plans to expand its presence in immunology with the introduction of a third program in 2025."

Pipeline update • Preclinical • Atopic Dermatitis • Chronic Spontaneous Urticaria